Illumina

Meet the MiSeq i100 Series – the new standard in sequencing simplicity with a 3-step setup, onboard DRAGEN analysis, and same-day results to accelerate genomic discovery and insights: https://bit.ly/4eTqugz

As part of a multi-year study in partnership with Providence and Microsoft Research, collaborators have found that CGP has identified more genetic anomalies compared to smaller gene panels, enabling precision therapies and improved outcomes for patients with advanced cancers. For more on this study and its impact: https://bit.ly/4fEsw50 #AMPath24

What makes a tool truly innovative? Simplicity and power. Emmanuel Naouri recently shared how the MiSeq i100 Series achieves both—transforming the way labs approach next-generation sequencing. Curious how it works? Don’t miss the chance to see it in person at #AMPath24, and read the feature in The Scientist: https://bit.ly/3ZhxkY3

“Illumina’s innovation engine continues to evolve to fit the diverse needs of our customers, and the expansion of our TruSight Oncology portfolio addresses both research and clinical customer needs.” At #AMPath24, Illumina product leaders Heather Robinson, MS MBA and Samyuktha Dasari (she/her) discussed the opportunity to expand comprehensive genomic profiling through RUO and IVD solutions.

Join us at #AMPath24 to discuss the latest research and growing evidence for the clinical utility of CGP, as well as challenges in precision medicine implementation. On Thursday, we will unveil plans for our newest cancer research assay, TruSight Oncology 500 v2, in a spotlight presentation on the TruSight Oncology portfolio and its role in enabling adoption of CGP. Stop by our booth to learn more!

Innovation doesn’t happen overnight, it’s often the result of relentless customer focus by experts like Dorothea Agius and Joe Cottrell on the Systems Integration team. By starting with feedback from customers, the team was able to prioritize applications and test the MiSeq i100 Series with their most adventurous research ideas in mind. Learn how Joe, Dorothea, and team brought together the best elements of Illumina sequencing technology to create a powerful, user-friendly platform for researchers everywhere: https://bit.ly/4hRrT9E

Eric Kelsic and his team are driven by one thing: Accelerating drug discovery. Hear how Dyno Therapeutics is finding ways to keep people healthier, longer with the help of Illumina technology.

“These results further illustrate the paradigm shift in clinical practice in oncology. Patients are seeing better outcomes from precision treatments based on a tumor’s molecular profile compared to conventional approaches used to treat cancer.” – Swaroop Aradhya, VP of Medical and Clinical Affairs at Illumina. Powerful study of CGP, in partnership with Providence and Microsoft Research, published today in the Journal of Clinical Oncology. Congratulations to John Fox, Bela Bapat, Pratheesh Sathyan PhD and the many team members who contributed to this important work over several years.

How do some cancers become more aggressive than others? Luigi Mancinelli, PhD and his team at the University of Pittsburg are using the NovaSeq X Plus and Partek Flow to pinpoint gene activity that may drive osteosarcoma metastasis. By targeting these genetic markers, they hope to block the tumor’s ability to develop metastasis and bring new hope to patients. Learn more about their critical work: https://bit.ly/3Z4FW4k

That’s a wrap on #ASHG24. The conference was an incredible opportunity to connect with our customers and hear about the latest advancements in genomics (and beyond!). Together, we reviewed our innovation roadmap, shared preliminary data highlighting the impact of these developments, and introduced customers to the MiSeq i100 Series for the very first time. From constellation mapped read technology to proteomics, single cell, and bioinformatics, we continue to partner with our customers to build the solutions that meet their needs. For more on our latest developments and partnerships: https://lnkd.in/gpHz9GJg